Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Sep 21;60(9):e0084321.
doi: 10.1128/jcm.00843-21. Epub 2022 Jun 13.

Antimicrobial Susceptibility Testing for Enterococci

Affiliations
Review

Antimicrobial Susceptibility Testing for Enterococci

Ayesha Khan et al. J Clin Microbiol. .

Abstract

Enterococci are major, recalcitrant nosocomial pathogens with a wide repertoire of intrinsic and acquired resistance determinants and the potential of developing resistance to all clinically available antimicrobials. As such, multidrug-resistant enterococci are considered a serious public health threat. Due to limited treatment options and rapid emergence of resistance to all novel agents, the clinical microbiology laboratory plays a critical role in deploying accurate, reproducible, and feasible antimicrobial susceptibility testing methods to guide appropriate treatment of patients with deep-seated enterococcal infections. In this review, we provide an overview of the advantages and disadvantages of existing manual and automated methods that test susceptibility of Enterococcus faecium and Enterococcus faecalis to β-lactams, aminoglycosides, vancomycin, lipoglycopeptides, oxazolidinones, novel tetracycline-derivatives, and daptomycin. We also identify unique problems and gaps with the performance and clinical utility of antimicrobial susceptibility testing for enterococci, provide recommendations for clinical laboratories to circumvent select problems, and address potential future innovations that can bridge major gaps in susceptibility testing.

Keywords: Enterococcus; antibiotic resistance; antimicrobial activity; antimicrobial agents; clinical methods; diagnostics; gram-positive bacteria; hospital infections; multidrug resistance; susceptibility testing.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Arias CA, Murray BE. 2012. The rise of the Enterococcus: beyond vancomycin resistance. Nat Rev Microbiol 10:266–278. doi:10.1038/nrmicro2761. - DOI - PMC - PubMed
    1. Arias CA, Contreras GA, Murray BE. 2010. Management of multidrug-Resistant enterococcal infections. Clin Microbiol Infect 16:555–562. doi:10.1111/j.1469-0691.2010.03214.x. - DOI - PMC - PubMed
    1. Miller WR, Murray BE, Rice LB, Arias CA. 2016. Vancomycin-resistant enterococci: therapeutic challenges in the 21st century. Infect Dis Clin North Am 30:415–439. doi:10.1016/j.idc.2016.02.006. - DOI - PubMed
    1. Maccallum WG, Hastings TW. 1899. A case of acute endocarditis caused by Micrococcus zymogenes (nov. spec.), with a description of the microorganism. J Exp Med 4:521–534. doi:10.1084/jem.4.5-6.521. - DOI - PMC - PubMed
    1. Lebreton F, Manson AL, Saavedra JT, Straub TJ, Earl AM, Gilmore MS. 2017. Tracing the enterococci from Paleozoic origins to the hospital. Cell 169:849–861. doi:10.1016/j.cell.2017.04.027. - DOI - PMC - PubMed

MeSH terms